Mwyngil Takes Non-GLP-1 Route Into Obesity Drug Race — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mwyngil Therapeutics is developing obesity treatments by studying weight-loss mechanisms that do not target the GLP-1 receptor, differentiating itself from the wave of startups chasing the same blockbuster drug class.
- Luba Greenwood, a biotech veteran, is serving as CEO of Mwyngil, and told STAT the role marks her first interview about the company.
- Greenwood said she joined Mwyngil specifically because she was "not interested in another 'me too' GLP-1, or GLP-1 plus something," calling such approaches "not very interesting science."
- GLP-1 drugs have gone from a largely unknown term to ubiquitous in American advertising — appearing on billboards, TV commercials, and in magazine articles — within just a few years.
- Most obesity-drug startups entering the multibillion-dollar weight-loss market are developing their own GLP-1 candidates, making Mwyngil's deliberate avoidance of the target a notable contrarian bet.
- Mwyngil (pronounced "mwin-gull") emerges into a market where GLP-1-based therapies from established pharma companies have already generated enormous public attention and commercial momentum.
Why it matters: Mwyngil's bet signals that despite GLP-1 therapies like Ozempic and Zepbound dominating investor attention and consumer advertising, a credible biotech veteran is wagering that alternative mechanisms can still win meaningful share of the multibillion-dollar obesity market — a contrarian thesis in a field where the vast majority of new entrants are racing to copy or combine GLP-1 approaches.
Ask SkimNews
